Replies to post #235319 on Biotech Values

[dewophile]

Thanks
I know the drugs were not compared head to head but it may be worth looking to see the data of steroids in DED in the literature and see how KALA stacks up
The lower IOP is enough to push adoption IMO, although this is another example of a class effect casting a shadow as the KALA label requires monitoring of IOP even though rates were similar to placebo in studies apparently

[north40000]

I do not know whether clinical trials of Amarin’s anti-inflammatory Vascepa for DES are contemplated. Whatever, several us who have taken Vascepa (my cost has been $36 per year) have reported clearing of DES in days. My DES was constant, but cleared within days of 1st administration of capsules in 2013, and remains gone today. I woke up one morning, and my eyes no longer felt cemented/glued shut.

BTW, take a look at TSOI’s website for its 2 PRs yesterday and today. Stem cells + COVID-19 = greatly increased survival in a University of Miami clinical trial. I will try to post a link:


https://pennystocks.news/therapeutics-solutions-jadicell-and-nanostilbene-make-a-big-statement-after-these-revelations-tsoi/

Amarin has its anti-inflammatory drug Vascepa in clinical trials as well for virus control in lungs, heart and arteries. Dr. Bhatt and a Canadian colleague have several trial sites open

How many Americans are estimated to have #heartdisease (❤)? Vote below and share your answer.#Amarin

— Amarin (@Amarincorp) October 28, 2020